NCT05417932View on ClinicalTrials.gov

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 26, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions
Hepatitis B Virus Related Hepatocellular CarcinomaHepatocellular Carcinoma Recurrent
Interventions
BIOLOGICAL

SCG101

Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.

Trial Locations (6)

10029

RECRUITING

New York, New York

10065

RECRUITING

New York, New York

169610

RECRUITING

Singapore, Singapore

228510

RECRUITING

Singapore, Singapore

Unknown

NOT_YET_RECRUITING

Hong Kong is., Hong Kong

RECRUITING

Hong Kong NT, Hong Kong

All Listed Sponsors
lead

SCG Cell Therapy Pte. Ltd.

INDUSTRY